Organon CEO pins high hopes on upcoming Humira biosimilar launch

What’s in store for Merck spinout Organon’s second year? Growth ambitions for birth control implant Nexplanon, plus tuned up sales expectations for its biosimilars and fertility businesses.

Altogether, that spread of offerings should help the company generate up to $6.4 billion in 2022 revenues, executives forecasted Thursday on the company’s full-year 2021 earnings call. But even as Organon moves ahead with its first full year of independent operations, execs took a chance on Thursday to talk up next year's big biosimilar launch.